
    
      Generic emtricitabine(FTC) has been approved for treatment of naive chronic hepatitis B(CHB)
      patients in China. Yet data are limited for this agent. The investigators design this trial
      to test the effect of FTC in Chinese CHB which including naive HBeAg positive and Negative
      CHB patients. Response guided therapy strategy is adopted for patients who can not achieve
      HBV DNA negativity at week 24 FTC treatment, which means FTC and adefovir are combined for
      these patients.
    
  